Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial
NCT02049307
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
108
Enrollment
OTHER
Sponsor class
Conditions
Inflammation
Fibrosis
Interventions
DRUG:
Losartan 100mg daily
DRUG:
Matching placebo
Sponsor
Hennepin Healthcare Research Institute